NasdaqCM:AXGN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

AxoGen, Inc., together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves.


Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has AxoGen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AXGN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.3%

AXGN

-7.3%

US Medical Equipment

2.9%

US Market


1 Year Return

-51.4%

AXGN

11.1%

US Medical Equipment

8.9%

US Market

Return vs Industry: AXGN underperformed the US Medical Equipment industry which returned 11.1% over the past year.

Return vs Market: AXGN underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

AXGNIndustryMarket
7 Day3.3%-7.3%2.9%
30 Day1.3%3.6%10.6%
90 Day-16.2%7.1%5.1%
1 Year-51.4%-51.4%12.0%11.1%11.4%8.9%
3 Year-34.1%-34.1%58.5%54.2%34.3%25.4%
5 Year214.1%214.1%105.6%84.4%60.7%42.7%

Price Volatility Vs. Market

How volatile is AxoGen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AxoGen undervalued compared to its fair value and its price relative to the market?

3.21x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AXGN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AXGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AXGN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: AXGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AXGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AXGN is good value based on its PB Ratio (3.2x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is AxoGen forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

34.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AXGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AXGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AXGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AXGN's revenue (17.2% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: AXGN's revenue (17.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AXGN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has AxoGen performed over the past 5 years?

-16.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AXGN is currently unprofitable.

Growing Profit Margin: AXGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AXGN is unprofitable, and losses have increased over the past 5 years at a rate of -16% per year.

Accelerating Growth: Unable to compare AXGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXGN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.2%).


Return on Equity

High ROE: AXGN has a negative Return on Equity (-22.4%), as it is currently unprofitable.


Next Steps

Financial Health

How is AxoGen's financial position?


Financial Position Analysis

Short Term Liabilities: AXGN's short term assets ($120.4M) exceed its short term liabilities ($19.5M).

Long Term Liabilities: AXGN's short term assets ($120.4M) exceed its long term liabilities ($1.2M).


Debt to Equity History and Analysis

Debt Level: AXGN is debt free.

Reducing Debt: AXGN currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AXGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AXGN has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 17.8% each year.


Next Steps

Dividend

What is AxoGen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AXGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AXGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AXGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AXGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AXGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Karen Zaderej (57yo)

8.75yrs

Tenure

US$999,963

Compensation

Ms. Karen Zaderej has been the Chief Executive Officer of AxoGen, Inc. since May 2010 and also has been its President since September 30, 2011. She was the Director of Viveve Medical Inc. from September 13 ...


CEO Compensation Analysis

Compensation vs Market: Karen's total compensation ($USD999.96K) is below average for companies of similar size in the US market ($USD2.15M).

Compensation vs Earnings: Karen's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Karen Zaderej
Chairman8.75yrsUS$999.96k1.66% $6.6m
Peter Mariani
Chief Financial Officer4.25yrsUS$548.03k0.052% $207.3k
Maria Martinez
Chief Human Resources Officer1.67yrsUS$460.48k0.0074% $29.4k
Gregory Freitag
Special Counsel & Director8.75yrsno data0.58% $2.3m
Eric Sandberg
Chief Commercial Officer1.42yrsUS$1.13m0.0040% $16.0k
Angelo Scopelianos
Vice President of Research & Development1.75yrsUS$554.14k0.0057% $22.6k
Michael Donovan
Vice President of Operations4.75yrsno data0.11% $437.3k
Brad Ottinger
General Counsel & Chief Compliance Officerno datano datano data
Gregory Davault
Vice President of Marketing2yrsno datano data
Isabelle Billet
Chief Strategy & Business Development Officer1.67yrsno data0.016% $65.3k

1.9yrs

Average Tenure

55yo

Average Age

Experienced Management: AXGN's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Karen Zaderej
Chairman8.75yrsUS$999.96k1.66% $6.6m
Gregory Freitag
Special Counsel & Director8.75yrsno data0.58% $2.3m
Guido Neels
Independent Director4.83yrsUS$180.00kno data
Robert Rudelius
Independent Director9.75yrsUS$188.75k0.11% $456.8k
Mark Gold
Independent Director8.75yrsUS$185.63k0.83% $3.3m
Bruce Mast
Member of Board of Advisorno datano datano data
David Muir
Member of Board of Advisorno datano datano data
Alan Levine
Independent Director1.08yrsUS$429.38kno data
Quentin Blackford
Independent Director1.08yrsUS$431.88k0.039% $155.7k
Amy Wendell
Independent Lead Director2.08yrsUS$201.88kno data

3.5yrs

Average Tenure

57.5yo

Average Age

Experienced Board: AXGN's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AxoGen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AxoGen, Inc.
  • Ticker: AXGN
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$398.415m
  • Shares outstanding: 39.76m
  • Website: https://www.axogeninc.com

Number of Employees


Location

  • AxoGen, Inc.
  • 13631 Progress Boulevard
  • Suite 400
  • Alachua
  • Florida
  • 32615
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AXGNNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 2011
LT3DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2011
0HKDLSE (London Stock Exchange)YesCommon StockGBUSDOct 2011

Biography

AxoGen, Inc., together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 04:49
End of Day Share Price2020/06/04 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.